Article
Evaluation of the selectivity and sensitivity of isoform- and mutation-specific RAS antibodies.
Science signaling - 26 Sept 2017
Waters Andrew M, Ozkan-Dagliyan Irem, Vaseva Angelina V, Fer Nicole, Strathern Leslie A, Hobbs G Aaron, Tessier-Cloutier Basile, Gillette William K, Bagni Rachel, Whiteley Gordon R, Hartley James L, McCormick Frank, Cox Adrienne D, Houghton Peter J, Huntsman David G, Philips Mark R, Der Channing J
Abstract excerpt
There is intense interest in developing therapeutic strategies for RAS proteins, the most frequently mutated oncoprotein family in cancer. Development of effective anti-RAS therapies will be aided by the greater appreciation of RAS isoform-specific differences in signaling events that support neoplastic cell growth. However, critical issues that require resolution to facilitate the success of these efforts...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.